EcoDrugPlus

Transient Receptor Potential Cation Channel Subfamily A Member 1-Like

Ensembl ID : ENSSTUG00000046098
Gene Symbol: LOC115157049
3 Cross references
149 Possible Orthologues:

Transient Receptor Potential Cation Channel Subfamily A Member 1-Like

Ensembl ID : ENSSTUG00000009035
Gene Symbol: LOC115169188
3 Cross references
149 Possible Orthologues:

Transient Receptor Potential Cation Channel Subfamily A Member 1-Like

Ensembl ID : ENSSTUG00000010778
Gene Symbol: LOC115195331
3 Cross references
194 Possible Orthologues:

Transmembrane Protein 160-Like

Ensembl ID : ENSSTUG00000009822
Gene Symbol: LOC115162996
2 Cross references
185 Possible Orthologues:

Transthyretin

Ensembl ID : ENSSTUG00000010910
Gene Symbol: TTR
3 Cross references
178 Possible Orthologues:

Trichohyalin-Like

Ensembl ID : ENSSTUG00000015140
Gene Symbol: LOC115170916
2 Cross references
190 Possible Orthologues:

Trichohyalin-Like

Ensembl ID : ENSSTUG00000005656
Gene Symbol: LOC115196279
2 Cross references
190 Possible Orthologues:

Tryptophan 5-Hydroxylase 1-Like

Ensembl ID : ENSSTUG00000010850
Gene Symbol: LOC115167134
3 Cross references
194 Possible Orthologues:

Tryptophan 5-Hydroxylase 1-Like

Ensembl ID : ENSSTUG00000023632
Gene Symbol: LOC115203199
3 Cross references
194 Possible Orthologues:

Tryptophan Hydroxylase 1

Ensembl ID : ENSSTUG00000017920
Gene Symbol: TPH1
3 Cross references
158 Possible Orthologues:

Tubulin Alpha Chain, Testis-Specific

Ensembl ID : ENSSTUG00000024528
Gene Symbol: LOC115203877
3 Cross references
312 Possible Orthologues:

Tubulin Alpha Chain, Testis-Specific-Like

Ensembl ID : ENSSTUG00000024498
Gene Symbol: LOC115203876
3 Cross references
310 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).